Seer Inc
SEER
View Detailed Chart
2.200USD
+0.140+6.80%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
123.92MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.80%
5 Days
+6.80%
1 Month
+7.32%
6 Months
+15.18%
Year to Date
-4.76%
1 Year
+24.29%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-18Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.000
Target Price
+52.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.17M.
Fairly Valued
The company’s latest PB is 0.43, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.75M shares, decreasing 24.64% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.20M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Ticker SymbolSEER
CompanySeer Inc
CEODr. Omid C. Farokhzad, M.D.
Websitehttps://seer.bio/
